These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 353340)

  • 21. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biochemical definition of uremia].
    Ringoir S
    Verh K Acad Geneeskd Belg; 1981; 43(2):105-19. PubMed ID: 7314875
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of small peptide in uremic serum by high-performance liquid chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1982 Mar; 228():292-7. PubMed ID: 7076752
    [No Abstract]   [Full Text] [Related]  

  • 25. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis.
    Fagugli RM; De Smet R; Buoncristiani U; Lameire N; Vanholder R
    Am J Kidney Dis; 2002 Aug; 40(2):339-47. PubMed ID: 12148107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uremic toxins and vitamin D metabolism.
    Hsu CH; Patel SR
    Kidney Int Suppl; 1997 Nov; 62():S65-8. PubMed ID: 9350684
    [No Abstract]   [Full Text] [Related]  

  • 27. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 28. Heme synthesis in anemia of the uremic state.
    Linkesch W; Stummvoll HK; Wolf A; Müller M
    Isr J Med Sci; 1978 Nov; 14(11):1173-6. PubMed ID: 750546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of alterations of uremic retention products upon platelet and peripheral nerve function.
    Lindsay RM; Bolton CF; Clark WF; Linton AL
    Clin Nephrol; 1983 Mar; 19(3):110-5. PubMed ID: 6839559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunodeficiency and an uremic toxin (author's transl)].
    Inamoto G; Ino Y
    Nihon Jinzo Gakkai Shi; 1976 Jun; 18(6):428-9. PubMed ID: 988348
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro cytotoxic properties of plasma samples from uremic patients.
    Delaporte C; Gros F; Jonsson C; Bergström J
    Clin Nephrol; 1982 May; 17(5):247-53. PubMed ID: 7094441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of two uremic toxins by nuclear magnetic resonance and mass spectrometry.
    Monti JP; Gallice P; Braguer D; Durand C; Murisasco A; Crevat A
    Adv Exp Med Biol; 1987; 223():223-6. PubMed ID: 3447439
    [No Abstract]   [Full Text] [Related]  

  • 33. Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation.
    Liabeuf S; Cheddani L; Massy ZA
    Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29874852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uremic toxins inhibit the platelet malonyldialdehyde production rate.
    Tanaka H; Itoh S; Yamagami S; Kishimoto T; Maekawa M; Ringoir S
    Adv Exp Med Biol; 1987; 223():115-8. PubMed ID: 3447425
    [No Abstract]   [Full Text] [Related]  

  • 35. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
    Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
    [No Abstract]   [Full Text] [Related]  

  • 36. Middle molecular weight substances and uremic polyneuropathy.
    Dukanović L; Petrović J; Potić J
    Acta Med Iugosl; 1990; 44(2):117-28. PubMed ID: 2162129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mass spectrometry in the search for uremic toxins.
    Niwa T
    Mass Spectrom Rev; 1997; 16(6):307-32. PubMed ID: 9703693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of an oral sorbent (AST-120) on the clinical course of uremic peak 2a in chronic renal failure].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
    Nihon Jinzo Gakkai Shi; 1987 Aug; 29(8):1003-11. PubMed ID: 3694879
    [No Abstract]   [Full Text] [Related]  

  • 40. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
    Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
    Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.